Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176251 | 0.79 | TSHR (0.40) | TSHR | |
| SCHEMBL13176961 | 0.78 | — | — | |
| SCHEMBL14780428 | 0.78 | — | — | |
| SCHEMBL3985694 | 0.78 | — | — | |
| SCHEMBL11878626 | 0.73 | — | — | |
| SCHEMBL6018777 | 0.73 | ALOX15 (0.48) | TSHR | |
| SCHEMBL83312 | 0.73 | — | — | |
| SCHEMBL8063782 | 0.73 | — | — | |
| SCHEMBL7155990 | 0.73 | — | — | |
| SCHEMBL8522054 | 0.71 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145018-A1 | Lipid-Polymer-Conjugates | ASTELLAS PHARMA EUROPE BV (NL) | 2010-06-10 | — | — | US | disclosed |
| US-20040254352-A1 | Lipid-polymer-conjugates | YAMANOUCHI EUROPE B.V. (NL) | 2004-12-16 | — | — | US | disclosed |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | ASTELLAS PHARMA EUROPE B.V. (NL) | 2004-12-02 | — | — | US | disclosed |
| EP-0908464-A1 | Process for the preparation of hydroxyphosphonates and their use as flame retardants in polymers | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145018-A1 | Lipid-Polymer-Conjugates | PARG, GLUL, PHOSPHO1 | TSHR 3339/4885 |
| US-20040254352-A1 | Lipid-polymer-conjugates | PARG, GLUL, PARN | TSHR 3338/4885 |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | PHOSPHO1, PARG, GLUL | TSHR 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.